Skip to main content
Journal cover image

Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors.

Publication ,  Journal Article
Boller, YC; Brandes, LM; Russell, RL; Lin, ZP; Patierno, SR; Kennedy, KA
Published in: Oncol Res
2000

Stress conditions associated with solid tumors lead to the formation of heterogeneous tumor cell subpopulations and insensitivity to cancer chemotherapeutics. In this report, we show that EMT6 mouse mammary tumor cells treated with the chemical stress, brefeldin A (BFA), or the physiological stress, hypoxia, develop resistance to the topoisomerase II (topoII) inhibitors teniposide and etoposide. BFA and hypoxia treatment did not alter intracellular drug concentrations, topoll protein levels, or inhibit topoII activity. BFA and hypoxia did cause the activation of the nuclear transcription factor NF-kappaB. We demonstrate that pretreatment with the synthetic cyclopentenone prostaglandin A1 (PGA1) inhibits stress-induced NF-kappaB activation and reverses BFA- and hypoxia-induced resistance. The reversal of BFA-induced resistance can occur when PGA1 is administered either before or several hours after the induction of stress. Taken together, these data support the involvement of NF-kappaB in stress-induced drug resistance, show that pharmacologic inhibitors of NF-kappaB can disrupt the biological consequences of stress, and imply that inhibitors of NF-kappaB may be useful agents to enhance the clinical efficacy of topoII-directed chemotherapeutics.

Duke Scholars

Published In

Oncol Res

DOI

ISSN

0965-0407

Publication Date

2000

Volume

12

Issue

9-10

Start / End Page

383 / 395

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Transfection
  • Topoisomerase II Inhibitors
  • Time Factors
  • Teniposide
  • Prostaglandins A
  • Oncology & Carcinogenesis
  • NF-kappa B
  • Mice
  • Medicinal & Biomolecular Chemistry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boller, Y. C., Brandes, L. M., Russell, R. L., Lin, Z. P., Patierno, S. R., & Kennedy, K. A. (2000). Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol Res, 12(9–10), 383–395. https://doi.org/10.3727/096504001108747846
Boller, Y. C., L. M. Brandes, R. L. Russell, Z. P. Lin, S. R. Patierno, and K. A. Kennedy. “Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors.Oncol Res 12, no. 9–10 (2000): 383–95. https://doi.org/10.3727/096504001108747846.
Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, Kennedy KA. Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol Res. 2000;12(9–10):383–95.
Boller, Y. C., et al. “Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors.Oncol Res, vol. 12, no. 9–10, 2000, pp. 383–95. Pubmed, doi:10.3727/096504001108747846.
Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, Kennedy KA. Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol Res. 2000;12(9–10):383–395.
Journal cover image

Published In

Oncol Res

DOI

ISSN

0965-0407

Publication Date

2000

Volume

12

Issue

9-10

Start / End Page

383 / 395

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Transfection
  • Topoisomerase II Inhibitors
  • Time Factors
  • Teniposide
  • Prostaglandins A
  • Oncology & Carcinogenesis
  • NF-kappa B
  • Mice
  • Medicinal & Biomolecular Chemistry